VT
VistaGen Therapeutics, Inc.
VTGN · NASDAQ
$0.24 -2.52% (-$0.01)
1M -12.49%
Market Cap $10.5M
P/E Ratio -
Div. Yield -
ROE 152.59%
Bulios Fair Price
$0.26
10.4% upside
Trenutna cena
$0.24
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica VTGN trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
3/9Valuation
72 /100
Cheap P/B 0.43x
P/S 4.18x
PEG N/A
Growth
100 /100
Growing Book val. growth 43.26%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak FCF margin 2,489.89%
Op. margin 2,784.33%
Gross margin 84.57%
Quality
1 /100
Poor Asset turnover 0.07x
ROA 189.22%
ROIC 275.77%
Debt
100 /100
Low Current ratio 3.07x
Debt/Equity 0.03x
Net debt/EBITDA N/A
Stability
23 /100
Unstable Profitable years 0
EPS volatility 53.04%
Beta 0.39x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o VTGN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Shawn K. Singh
Employees
41
Headquarters
South San Francisco
Prihajajoči dogodki
12 NOV.
Earnings
Upcoming earnings report